Episode 046: Myeloma Series, Pt.7- Autologous Transplant in Multiple Myeloma
The Fellow on Call: The Heme/Onc Podcast
00:00
Why We Still Do What We Do
Viva could allude to being off treatment if we can get a patient to that operational cure where they may not need treatment. And you'll see how Numer trials and maintenance strategies are looking at ways that we can do a risk-adapted approach. We think PFS1 is going to be longer in duration than PFS2, probably because as people go through subsequent rounds of treatment, we're selecting more resistant subclones.
Transcript
Play full episode
